Literature DB >> 19159989

Initial clinical experience with a selective A2A receptor agonist, regadenoson, in a patient with end-stage renal disease on hemodialysis.

Saaron Laighold1, Regina Druz.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19159989     DOI： 10.1007/s12350-008-9043-z

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN： 1071-3581            Impact factor:   5.952


× No keyword cloud information.
  3 in total

Review 1.  Adenosine stress protocols for myocardial perfusion imaging.

Authors:  Sabahat Bokhari; Edward P Ficaro; Benjamin D McCallister
Journal:  J Nucl Cardiol       Date:  2007 May-Jun       Impact factor: 5.952

2.  Regadenoson pharmacokinetics and tolerability in subjects with impaired renal function.

Authors:  Toufigh Gordi; Brent Blackburn; Hsiao Lieu
Journal:  J Clin Pharmacol       Date:  2007-07       Impact factor: 3.126

3.  Effects of age, gender, obesity, and diabetes on the efficacy and safety of the selective A2A agonist regadenoson versus adenosine in myocardial perfusion imaging integrated ADVANCE-MPI trial results.

Authors:  Manuel D Cerqueira; Patricia Nguyen; Peter Staehr; S Richard Underwood; Ami E Iskandrian
Journal:  JACC Cardiovasc Imaging       Date:  2008-05
  3 in total
  5 in total

Review 1.  The emerging role of the selective A2A agonist in pharmacologic stress testing.

Authors:  Anthony S Gemignani; Brian G Abbott
Journal:  J Nucl Cardiol       Date:  2010-06       Impact factor: 5.952

2.  ASNC imaging guidelines for SPECT nuclear cardiology procedures: Stress, protocols, and tracers.

Authors:  Milena J Henzlova; W Lane Duvall; Andrew J Einstein; Mark I Travin; Hein J Verberne
Journal:  J Nucl Cardiol       Date:  2016-06       Impact factor: 5.952

3.  The safety and tolerability of regadenoson in patients with end-stage renal disease: the first prospective evaluation.

Authors:  Rami Doukky; Maria Octavia Rangel; Marwan Wassouf; Rizcallah Dick; Ammar Alqaid; Raysa Morales Demori
Journal:  J Nucl Cardiol       Date:  2012-12-13       Impact factor: 5.952

4.  Safety of regadenoson as a pharmacologic stress agent for myocardial perfusion imaging in chronic kidney disease patients not on hemodialysis.

Authors:  Gurunanthan Palani; Zehra Husain; Rafael Cabrera Salinas; Vanji Karthikeyan; Aarthee S Karthikeyan; Karthik Ananthasubramaniam
Journal:  J Nucl Cardiol       Date:  2011-05-04       Impact factor: 5.952

Review 5.  Adenosine: an old drug newly discovered.

Authors:  Holger K Eltzschig
Journal:  Anesthesiology       Date:  2009-10       Impact factor: 7.892
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.